Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296472 | 0.90 | ALDH1A1 (0.45) | SMN1; SMN2PKMMEN1KMT2AKDM4E | |
| SCHEMBL30079470 | 0.89 | SMN1; SMN2 (0.40) | GAASMN1; SMN2TDP1PKMCYP3A4 | |
| SCHEMBL4021391 | 0.89 | SMN1; SMN2 (0.42) | GAASMN1; SMN2TDP1PKMCYP3A4 | |
| SCHEMBL30950122 | 0.82 | F2RL1 (0.33) | ALDH1A1 | |
| SCHEMBL30079054 | 0.82 | ALDH1A1 (0.34) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4761780 | 0.81 | SMN1; SMN2 (0.32) | GAASMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL21296458 | 0.81 | F2RL1 (0.33) | GAAKDM4EALDH1A1 | |
| SCHEMBL15509075 | 0.81 | KMT2A (0.40) | GAASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL11890433 | 0.81 | ALDH1A1 (0.36) | GAASMN1; SMN2PKMCYP3A4CYP2C9 | |
| SCHEMBL4013481 | 0.80 | SMN1; SMN2 (0.33) | GAASMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737684-B1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-11-16 | — | — | EP | disclosed |
| EP-3755699-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200392161-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRÖDINGER, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165073-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392161-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | GAA 753/4885SMN1; SMN2 2591/4885TDP1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.